Exploring prolonged-release tacrolimus for children after liver transplant
Official title: Prospective, Multicenter Clinical Study of Prolonged-release Tacrolimus in Stable Pediatric Liver Transplant Recipients
Run by RenJi Hospital · NCT06183892 · Data updated 2026-11-12
This study is testing if a new long-lasting version of tacrolimus can help children who have had a liver transplant avoid rejection and stay healthy by making it easier for them to take their medicine.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 6 Months to 18 Years |
| Sex | All |
| Enrollment | 80 (estimated) |
| Sponsor | RenJi Hospital Academic / other |
| Locations | 1 site (Shanghai) |
| Status | Recruiting |
| Started | March 4, 2024 |
| Main results expected | July 1, 2025 |
| Study ends | July 1, 2026 |
| Registry record updated | December 18, 2024 |
| Trial ID | NCT06183892 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are children aged 18 years or younger who have undergone liver transplantation and have been stable on immediate-release tacrolimus for at least three months.
✕Probably not a fit
Patients who have undergone multi-organ transplants or have a history of allergic reactions to tacrolimus may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the effects of sustained-release tacrolimus capsules on preventing acute rejection and fibrosis in pediatric liver transplant recipients. Tacrolimus is a vital immunosuppressant, but adherence can decline over time, leading to serious complications. By switching to a sustained-release formulation, the study aims to improve medication compliance and overall graft survival. Participants will be monitored for biopsy-proven acute rejection and liver health over the course of the study.
Why it matters
Potential benefit: If successful, this approach could significantly reduce the incidence of acute rejection and improve long-term liver function in pediatric transplant recipients.
How similar studies have gone: Previous studies in adult populations have shown that sustained-release tacrolimus can improve transplant outcomes, suggesting potential benefits in pediatric cases as well.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Children (≤18 years old) who have undergone liver transplantation, with no gender limitations; 2. Able to completely swallow capsules; 3. Have been using immediate-release tacrolimus for at least three months prior to study enrollment; 4. Have normal blood count, liver and kidney function, coagulation function, and considered clinically stable by researchers; 5. Undergo a programmed liver biopsy; Exclusion Criteria: 1. Multi-organ combined transplantation or multiple liver transplantation; 2. Adjuvant liver transplantation or use of bioartificial liver therapy; 3. ABO incompatible children with liver transplantation; 4. Allergic to tacrolimus; 5. Participation in any other clinical study within 3 months prior to enrollment; 6. Use of tacrolimus sustained release capsules before enrollment; 7. Tacrolimus trough concentration lower than 3.5 ng/ml at the time of screening;
Where it's running
-
Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University
Shanghai, China Recruiting
Study contacts
- Principal investigator: Hao Feng, MD., Ph.D — Dept. Liver Surgery, Renji Hospital, School of Medicine, SJTU
- Study coordinator: Hao Feng, MD., Ph.D
- Email: surgeonfeng@live.com
- Phone: 008615000901110
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Expanding HIV-positive donor livers for HIV-positive recipients
This study tests whether liver transplants from HIV-positive donors to HIV-positive recipients are safe regarding opportunistic infections and cancer.
-
Magnetic Resonance Cholangiopancreatography to help living liver donors and their recipients
This study tests whether preoperative MRCP imaging can help select living liver donors and reduce biliary complications in recipients.
-
Reducing Immunosuppression by 50% in Young Liver Transplant Recipients
This study tests whether cutting the immunosuppressive medicine by half in children with liver transplants is safe and effective.
-
Preoperative Carbohydrate Loading Before Liver Transplant
This study tests whether drinking a carbohydrate beverage before anesthesia helps liver transplant patients recover faster.
-
Doctor counseling plus smartphone apps to support healthy eating and activity after liver or kidney transplant
This program tries whether doctor-delivered lifestyle counseling combined with two smartphone apps can help people aged 60 and older who had a liver or kidney transplant eat healthier and be more active.
-
Long-term health of children born to mothers who had a solid organ transplant
This project will look for long-term heart, kidney, and immune system problems in people aged 16 and older who were born to mothers who had a kidney, liver, pancreas, heart, or lung transplant.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.